top of class

Houston universities maintain top spots on best entrepreneurship program rankings

University of Houston and Rice University have again been recognized for their programs for entrepreneurship. Photo courtesy of UH.edu

Houston entrepreneurs, take note. Rice University and the University of Houston again are at the top of their class among the country’s best entrepreneurship programs.

Rice’s Jones Graduate School of Business appears at No. 1 on a new list from The Princeton Review of the best graduate programs for entrepreneurs. Rice also lands at No. 5 in Poets and Quants’ new ranking of the best online MBA programs, up from seventh place last year.

Meanwhile, UH’s C.T. Bauer College of Business shows up at No. 1 in The Princeton Review’s ranking of the best undergraduate programs for entrepreneurs.

For both Rice and UH, this marks the fourth consecutive year for No. 1 rankings in the graduate and undergraduate categories, respectively, from The Princeton Review.

“Appearing in the number one spot for the fourth year running cements reputationally what our students know innately, that Rice’s comprehensive suite of programming and education provides true practical value for founders and innovators,” Yael Hochberg, head of Rice’s Entrepreneurship Initiative, says in a news release.

The Princeton Review notes that graduates of Rice’s entrepreneurship program have raised more than $1.2 billion in funding for their startups over the past five years. During the same timeframe, UH entrepreneurship alumni have launched 779 startups.

UH’s Cyvia and Melvyn Wolff Center for Entrepreneurship “is the crown jewel of the Bauer College. But it is also a testament to the support we have received from the community,” Paul Pavlou, dean of the college, says in a news release. “In the last several years, we have been fortunate to receive numerous generous donations that are funding life-changing scholarships for our students, enabling us to recruit and train the next generation of successful entrepreneurs.”

Other Texas schools featured in The Princeton Review rankings include:

  • University of Texas at Austin, No. 5 for best graduate entrepreneurship program and No. 2 for best undergraduate entrepreneurship program
  • University of Texas at Dallas, No. 12 for best graduate entrepreneurship program and No. 25 for best undergraduate entrepreneurship program
  • Texas A&M University-College Station, No. 24 for best graduate entrepreneurship program and No. 36 for best undergraduate entrepreneurship program
  • Baylor University in Waco, No. 6 for best undergraduate entrepreneurship program
  • Texas Tech University in Lubbock, No. 12 for best undergraduate entrepreneurship program

“The rate of entrepreneurship and business creation has hit record highs in recent years,” says Jason Feifer, editor in chief of Entrepreneur magazine, which published The Princeton Review rankings. “We’re seeing more people seeking insight on how to become successful entrepreneurs. With this list of schools, aspiring entrepreneurs have a valuable reference for exploring schools that excel at helping young leaders expand their business skillsets and networks with an entrepreneurial ecosystem.”

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted